Global healthcare companies such as J&J and Pfizer lose billions of dollars in revenues when patents expire on blockbuster products. When Pfizer’s Lipitor went off patent two years ago, sales plunged from about $11 billion to a forecast $3 billion. Some patents are tied to complex molded parts used as delivery systems. The window to recoup enormous R&D costs may be just 14 years in a lucrative market like the United States. Tagging Options Domain:  All Sites Keywords:  NyproMold Zeiss read more

Read this article:
CT scanning speeds product qualification in healthcare